IACS-16559

N/A

Report date: 2024/05/11 18:34:09
NME

Base Information

Drug NameIACS-16559
Drug Alias NameIACS-16559
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Actionp300-CBP transcription factors inhibitors
Targetsp300-CBP transcription factors
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A